Results 81 to 90 of about 7,843 (191)

Iloprost: Old and New Indications.

open access: yes
Iloprost is a synthetic long-acting prostacyclin-analog drug used to treat various vascular diseases. The Federal Drug Administration approved the drug in 2004 for pulmonary arterial hypertension, and it has since been shown to be helpful in other ...
Peterson, S. J.   +4 more
core   +1 more source

Iloprost, a prostacyclin (PGI2) analogue, reduces liver injury in hepatic ischemiareperfusion in rats Iloprost, um análogo da prostaciclina (PGI2), reduz danos da isquemia/reperfusão hepática em ratos

open access: yesActa Cirúrgica Brasileira, 2009
PURPOSE: To evaluate the effects of iloprost a prostacyclin analogue on the hepatic IR injury in rats. METHODS: Forty male Sprague-Dawley rats (250-300 g) were divided into four groups each containing 10 rats;(1)- controls: data from unmanipulated ...
Ercan Gedik   +5 more
doaj   +1 more source

Asymmetrische Totalsynthese von 16(S)-Iloprost und 3-Oxa-16(S)-Iloprost mittels der Azoen-Strategie [PDF]

open access: yes, 2005
The present dissertation describes completely stereocontrolled asymmetric syntheses of 16S-iloprost and of 16S-3-oxa-iloprost by a azoene strategy. As Ilomedin and Ventavis registrated iloprost (1:1 mixture of diastereomers at C16) serves as a drug ...
Kramp, Guido Johannes
core   +1 more source

Short- and Long-Term Effects of Inhaled Iloprost Therapy in Children With Pulmonary Arterial Hypertension [PDF]

open access: yes, 2008
ObjectivesThis study investigated the short- and long-term outcome of children with pulmonary arterial hypertension (PAH) treated with inhaled iloprost.BackgroundInhaled iloprost has been approved for the treatment of adults with PAH, but little is known
Mallory, George B.   +10 more
core   +1 more source

User preference for a portable syringe pump for iloprost infusion

open access: yes, 2015
Antonella Laria,1 Alfredo Maria Lurati,1 Katia Angela Re,1 Maria Grazia Marrazza,1 Daniela Mazzocchi,1 Alberto Farina,2 Magda Scarpellini,1 1Department of Rheumatology, Fornaroli Hospital, Magenta, Milan, Italy; 2Medical Affairs Department, Italfarmaco S.
Laria A   +6 more
core  

Proposal of early retreatment with iloprost in partially responsive patients with bone marrow edema syndrome: a case report

open access: yesItalian Journal of Medicine, 2012
Background Avascular Necrosis (AVN) is defined as the cellular death of bone components due to an alteration of the blood supply, resulting in Edema of the Bone Marrow (BME), structural collapse and bone destruction.
Simone Meini, Grazia Panigada
doaj   +1 more source

Iloprost infusion does not reduce oxidative stress in systemic sclerosis.

open access: yes, 2008
Systemic sclerosis is a connective tissue disease in which oxidative stress represents an important player among the complex pathogenetic mechanisms of the disease.
Volpe A   +6 more
core   +1 more source

Circulatory Effects of Inhaled Iloprost in the Newborn Preterm Lamb.

open access: yes, 2009
Inhaled nitric oxide (iNO) has an established role in the treatment of pulmonary hypertension in the newborn. However, costs and potential toxicity associated with iNO have generated interest in alternative inhaled selective pulmonary vasodilators such ...
Erkki Pesonen   +20 more
core   +1 more source

The Combined Effect of Iloprost and N-Acetylcysteine in Preventing Spinal Cord Ischemia in Rabbits [PDF]

open access: yes, 2006
ObjectivesThis study investigated the cytoprotective effects of N-acetylcysteine (NAC) and iloprost on spinal cord ischemia in an experimental model.Materials and methodsThirty-five (male) New Zealand white rabbits were included in five study groups (n=7,
Boga, M.   +7 more
core   +1 more source

Vasorelaxant effect of iloprost on isolated human internal mammary artery

open access: yes, 2007
In this study, vasodilator effect of iloprost on KCl-induced contraction in human internal mammary artery (IMA) was studied and compared with other vasodilators papaverin and diltiazem.
Sariosmanoglu, O. N.   +15 more
core   +1 more source

Home - About - Disclaimer - Privacy